web analytics
1.8 C
Munich
Friday, December 2, 2022

Endonovo Therapeutics Inc (OTCMKTS: ENDV) Heats Up

Endonovo Therapeutics Inc (OTCMKTS: ENDV) saw an explosive move up Friday after the Company announced a shareholder letter from its Chief Executive Officer, Alan Collier:

To highlight some of our accomplishments, this year:

  • Signing two marketing agreements with well established medical device sales organizations
  • Establishment and expansion of a rapidly growing sales department
  • The completion of the purchase price to the seller of the SofPulse Technology
  • The new Roma medical device is on schedule for release in Q1 of 2019

Endonovo Therapeutics Inc (OTCMKTS: ENDV) bills itself as a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company’s current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. There is a lot to get excited about on ENDV; this is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, already doing sales with a number of important distribution agreements in place.

Endonovo non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company’s non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

Earlier this year ENDV announced the first commercial sales of SofPulse™, its non-invasive, wearable Electroceutical™ device. SofPulse™ is the Company’s FDA-Cleared Electroceutical™ System for the palliative treatment of post-operative pain and edema in superficial soft tissues. Furthermore, the Company announced it is seeking distribution partners in Europe for SofPulse™, which is CE-Marked for the promotion of wound healing, reduction of pain and post-operative edema.

To Find out the inside Scoop on ENDV Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Animals treated three times per day with the Company’s Pulsed Electromagnetic Fields (PEMF) device had significantly higher blood flow (ratio of blood flow of the ischemic limb to blood flow of non-ischemic limb) at day 7 and 14 (57% and 71%, versus 36% and 52%) versus the controls. Furthermore, animals treated with PEMF three times per day had significantly improved foot movement scores and less tissue damage in the ischemic hind limb versus the controls.

In June ENDV said the first patient has been enrolled in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company’s senior secured Series C Preferred Stock financing.

Recently ENDV has signed a number of distribution agreement for the distribution of SofPulse™, its non-invasive Electroceutical™ Therapy for post-operative pain relief and reduction of swelling. The Company signed agreements with Plagens Medical Consultants as well as Magniant, LLC which includes sales, marketing and distribution targeting the VA, DOD, Indian Health Services, Long Term Care Institutions, Pain Clinics, Wound Clinics and Private Practices among physicians.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $11.4 million market valuation ENDV has $665k in the treasury, significant debt and reported revenues of $19,826 for the 6 months ended June, 30, 2018. ENDV is an exciting story in small caps: ENDV is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies, already doing sales with a number of important distribution agreements in place. The Company continues developing a portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. We will be updating on ENDV when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENDV.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in ENDV either long or short and we have not been compensated for this article.

Ali Raza
A journalist, with experience in web journalism and marketing. Ali holds a master degree in finance and enjoys writing about cryptocurrencies and fintech. Ali’s work has been published on a number of cryptocurrency publications.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.